QUOTE AND NEWS
Benzinga  May 4  Comment 
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) reported net income attributable to its shareholders of $6.61 million or $0.30 a share, which was significantly higher than $754 thousand or $0.04 a share in the year-ago quarter. However, excluding...
GenEng News  Apr 29  Comment 
Therapeutic antibodies designed to block immune checkpoint receptors or activate immunostimulatory receptors are a promising strategy to treat cancer and function by modulating a patient’s own immune system. Co-engagement of multiple immune...
Benzinga  Apr 28  Comment 
Aduro Biotech, Inc. (Nasdaq: ADRO) today announced the publication of a pivotal paper elucidating the roles of B cell maturation antigen (BCMA) and its ligand A PRoliferation-Inducing Ligand (APRIL) in multiple myeloma, highlighting the potential...
Benzinga  Apr 13  Comment 
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a unique biotech play that offers long-term staged growth profile, according to a note from Stephens, which initiated coverage of the stock with an Overweight (Volatile) rating. The brokerage has...
Benzinga  Apr 7  Comment 
Viking Therapeutics Inc (NASDAQ: VKTX) is up 87 percent on Thursday, trading at $2.66. The clinical-stage biopharmaceutical company was incorporated in 2012, and went public in 2015. At just shy of a year old, the metabolic/endocrine solutions...
Benzinga  Apr 7  Comment 
The European Commission [EC] has expanded the label for Revolade [Promacta], developed by Ligand Pharmaceuticals Inc. (NASDAQ: LGND) partner Novartis AG (ADR) (NYSE: NVS), by approving the drug for children older than 1 year with chronic ITP. Roth...
GenEng News  Mar 30  Comment 
For drug developers, G-protein coupled receptors (GPCRs) are dearly sought trophies. Many GPCRs have already been “bagged”—about 30% of all prescription drugs target a GPCR—but GPCR hunts continue, even though the quarry that remains...





You may also be interested in articles related to Ligand Pharmaceuticals (LGND):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki